{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:40:21Z","timestamp":1794674421906,"version":"4.9.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapse after CD19-directed chimeric antigen receptor (CAR)\u2013modified T cells remains a substantial challenge. Short CAR T-cell persistence contributes to relapse risk, necessitating novel approaches to prolong durability. CAR T-cell reinfusion (CARTr) represents a potential strategy to reduce the risk of or treat relapsed disease after initial CAR T-cell infusion (CARTi). We conducted a retrospective review of reinfusion of murine (CTL019) or humanized (huCART19) anti\u2013CD19\/4-1BB CAR T cells across 3 clinical trials or commercial tisagenlecleucel for relapse prevention (peripheral B-cell recovery [BCR] or marrow hematogones \u22646\u00a0months after CARTi), minimal residual disease (MRD) or relapse, or nonresponse to CARTi. The primary endpoint was complete response (CR) at day 28 after CARTr, defined as complete remission with B-cell aplasia. Of 262 primary treatments, 81 were followed by \u22651 reinfusion (investigational CTL019, n\u00a0= 44; huCART19, n\u00a0= 26; tisagenlecleucel, n\u00a0= 11), representing 79 patients. Of 63 reinfusions for relapse prevention, 52% achieved CR (BCR, 15\/40 [38%]; hematogones, 18\/23 [78%]). Lymphodepletion was associated with response to CARTr for BCR (odds ratio [OR], 33.57; P\u00a0=\u00a0.015) but not hematogones (OR, 0.30; P\u00a0=\u00a0.291). The cumulative incidence of relapse was 29% at 24 months for CR vs 61% for nonresponse to CARTr (P\u00a0= .259). For MRD\/relapse, CR rate to CARTr was 50% (5\/10), but 0\/8 for nonresponse to CARTi. Toxicity was generally mild, with the only grade \u22653 cytokine release syndrome (n\u00a0= 6) or neurotoxicity (n\u00a0= 1) observed in MRD\/relapse treatment. Reinfusion of CTL019\/tisagenlecleucel or huCART19 is safe, may reduce relapse risk in a subset of patients, and can reinduce remission in CD19+ relapse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012885","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T21:25:16Z","timestamp":1708637116000},"page":"2182-2192","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2542-2061","authenticated-orcid":false,"given":"Regina M.","family":"Myers","sequence":"first","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Devine","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-6992","authenticated-orcid":false,"given":"Yimei","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Biomedical and Health Informatics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"4Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lawrence","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-4064","authenticated-orcid":false,"given":"Allison Barz","family":"Leahy","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Biomedical and Health Informatics, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Vernau","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Callahan","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Baniewicz","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-8034","authenticated-orcid":false,"given":"Stephan","family":"Kadauke","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"5Department of Pathology and Laboratory Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"McGuire","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Wertheim","sequence":"additional","affiliation":[{"name":"5Department of Pathology and Laboratory Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-5454","authenticated-orcid":false,"given":"Irina","family":"Kulikovskaya","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"7Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"8Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"DiNofia","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"9Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8030-7595","authenticated-orcid":false,"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wray","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-8736","authenticated-orcid":false,"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"},{"name":"2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"8Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"16","key":"2024051415212993200_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024051415212993200_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2024051415212993200_bib3","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024051415212993200_bib4","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"9967","key":"2024051415212993200_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"2024051415212993200_bib6","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024051415212993200_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024051415212993200_bib8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024051415212993200_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2024051415212993200_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024051415212993200_bib11","doi-asserted-by":"crossref","first-page":"e004483","DOI":"10.1136\/jitc-2021-004483","article-title":"Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation","volume":"10","author":"Holland","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2024051415212993200_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024051415212993200_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 1","key":"2024051415212993200_bib14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2024051415212993200_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2024051415212993200_bib16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024051415212993200_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024051415212993200_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2182\/2224920\/blooda_adv-2024-012885-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2182\/2224920\/blooda_adv-2024-012885-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:22:27Z","timestamp":1715700147000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2182\/515039\/Reinfusion-of-CD19-CAR-T-cells-for-relapse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012885","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}